Editas Medicine, Inc. (EDIT)

5.32 +0.10 (+1.92%) 收市：04:00PM EDT

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

版塊: Healthcare
行業: Biotechnology
全職員工: 265

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Gilmore O'Neill M.D.	President, CEO & Director	1.04M	無	1964
Mr. Erick J. Lucera C.F.A., CPA	CFO & Executive VP	911.46k	無	1968
Dr. Linda C. Burkly Ph.D.	Executive VP & Chief Scientific Officer	522.44k	無	1957
Dr. Baisong Mei M.D., Ph.D.	Executive VP & Chief Medical Officer	654.9k	無	1964
Dr. Feng Zhang Ph.D.	Co-Founder & Scientific Advisory Board Member	無	無	無
Dr. George McDonald Church Ph.D.	Co-Founder & Scientific Advisory Board Member	無	無	1954
Cristi Barnett	Corporate Communications & Investor Relations	無	無	無
Ms. Charlene Stern J.D., Ph.D.	Executive VP & General Counsel	無	無	無
Ms. Linea Aspesi	Executive VP & Chief People Officer	無	無	1970
Ms. Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	無	無	1966

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

公司管治

截至 2024年4月1日 止，Editas Medicine, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：2；董事會：4；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。